Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Neumora Therapeutics, Inc. has received a consensus rating of "Hold" from analysts, with three sell, four hold, and three buy recommendations among the ten rating firms.
• The average 1-year price target set by analysts for Neumora's stock is $7.14, while shares currently trade at $1.83.
• Institutional ownership of Neumora Therapeutics stands at 47.65%, with significant changes in positions among various hedge funds and institutional investors in recent quarters.

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) has received an average recommendation of "Hold" from the ten ratings firms that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $7.1429.

Several research analysts have weighed in on the company. Mizuho boosted their price target on Neumora Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. JPMorgan Chase & Co. downgraded Neumora Therapeutics from a "neutral" rating to an "underweight" rating in a report on Tuesday, September 16th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Neumora Therapeutics in a report on Saturday, September 27th.

Institutional Trading of Neumora Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in NMRA. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Neumora Therapeutics during the 4th quarter worth $770,000. California State Teachers Retirement System increased its holdings in shares of Neumora Therapeutics by 793.5% during the 4th quarter. California State Teachers Retirement System now owns 54,457 shares of the company's stock worth $577,000 after buying an additional 48,362 shares during the last quarter. Lunate Capital Ltd acquired a new stake in shares of Neumora Therapeutics during the 1st quarter worth $2,124,000. Cerity Partners LLC increased its holdings in Neumora Therapeutics by 24.0% in the 1st quarter. Cerity Partners LLC now owns 302,505 shares of the company's stock valued at $303,000 after purchasing an additional 58,597 shares in the last quarter. Finally, CWM LLC increased its holdings in Neumora Therapeutics by 7,124.4% in the 1st quarter. CWM LLC now owns 25,213 shares of the company's stock valued at $25,000 after purchasing an additional 24,864 shares in the last quarter. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Trading Up 2.8%

Shares of NMRA opened at $1.83 on Friday. The stock has a fifty day moving average of $1.70 and a two-hundred day moving average of $1.19. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.54 and a current ratio of 10.54. The company has a market capitalization of $296.37 million, a PE ratio of -1.17 and a beta of 2.92. Neumora Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.05. As a group, analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.